Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells

The overexpression of ATP binding cassette (ABC) transporters makes tumor cells simultaneously resistant to several cytotoxic drugs. Impairing the energy metabolism of multidrug resistant (MDR) cells is a promising chemosensitizing strategy, but many metabolic modifiers are too toxic in vivo. We pre...

Full description

Bibliographic Details
Main Authors:	Kopecka, Joanna, Porto, Stefania, Lusa, Sara, Gazzano, Elena, Salzano, Giuseppina, Giordano, Antonio, Desiderio, Vincenzo, Ghigo, Dario, Caraglia, Michele, De Rosa, Giuseppe, Riganti, Chiara
Format:	Online
Language:	English
Published:	Impact Journals LLC 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741618/

id	pubmed-4741618
recordtype	oai_dc
spelling	pubmed-47416182016-03-03 Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells Kopecka, Joanna Porto, Stefania Lusa, Sara Gazzano, Elena Salzano, Giuseppina Giordano, Antonio Desiderio, Vincenzo Ghigo, Dario Caraglia, Michele De Rosa, Giuseppe Riganti, Chiara Research Paper The overexpression of ATP binding cassette (ABC) transporters makes tumor cells simultaneously resistant to several cytotoxic drugs. Impairing the energy metabolism of multidrug resistant (MDR) cells is a promising chemosensitizing strategy, but many metabolic modifiers are too toxic in vivo. We previously observed that the aminobisphosphonate zoledronic acid inhibits the activity of hypoxia inducible factor-1α (HIF-1α), a master regulator of cancer cell metabolism. Free zoledronic acid, however, reaches low intratumor concentration. We synthesized nanoparticle formulations of the aminobisphosphonate that allow a higher intratumor delivery of the drug. We investigated whether they are effective metabolic modifiers and chemosensitizing agents against human MDR cancer cells in vitro and in vivo. Impact Journals LLC 2015-09-09 /pmc/articles/PMC4741618/ /pubmed/26372812 Text en Copyright: © 2015 Kopecka et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Kopecka, Joanna Porto, Stefania Lusa, Sara Gazzano, Elena Salzano, Giuseppina Giordano, Antonio Desiderio, Vincenzo Ghigo, Dario Caraglia, Michele De Rosa, Giuseppe Riganti, Chiara
spellingShingle	Kopecka, Joanna Porto, Stefania Lusa, Sara Gazzano, Elena Salzano, Giuseppina Giordano, Antonio Desiderio, Vincenzo Ghigo, Dario Caraglia, Michele De Rosa, Giuseppe Riganti, Chiara Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells
author_facet	Kopecka, Joanna Porto, Stefania Lusa, Sara Gazzano, Elena Salzano, Giuseppina Giordano, Antonio Desiderio, Vincenzo Ghigo, Dario Caraglia, Michele De Rosa, Giuseppe Riganti, Chiara
author_sort	Kopecka, Joanna
title	Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells
title_short	Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells
title_full	Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells
title_fullStr	Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells
title_full_unstemmed	Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells
title_sort	self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells
description	The overexpression of ATP binding cassette (ABC) transporters makes tumor cells simultaneously resistant to several cytotoxic drugs. Impairing the energy metabolism of multidrug resistant (MDR) cells is a promising chemosensitizing strategy, but many metabolic modifiers are too toxic in vivo. We previously observed that the aminobisphosphonate zoledronic acid inhibits the activity of hypoxia inducible factor-1α (HIF-1α), a master regulator of cancer cell metabolism. Free zoledronic acid, however, reaches low intratumor concentration. We synthesized nanoparticle formulations of the aminobisphosphonate that allow a higher intratumor delivery of the drug. We investigated whether they are effective metabolic modifiers and chemosensitizing agents against human MDR cancer cells in vitro and in vivo.
publisher	Impact Journals LLC
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741618/
_version_	1613533825425473536

Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells

Similar Items